The China-based group buying service is set to float at the top of its range today, with Tencent remaining its largest investor.

The Rakuten-backed social media platform, valued at more than $12bn a year ago, plans to float in the next year.

Hepalink-backed Aridis Pharmaceuticals has filed to raise up to $34.5m that will support clinical trials for three immunotherapy drug candidates.

The Yahoo Japan and MCN-backed digital media company priced its initial public offering last month before failing to float.

The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.

The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

The SR One-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

The Roche-backed antibody developer floated above its range and has seen its stock almost double in price.

The Tencent-backed livestreaming platform is favouring the US for an initial public offering expected to raise between $600m and $700m.

UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.